Cardiometabolic Disease and Novel Therapies: SGLT2 Inhibitors and GLP1 Agonists

Dr. Daniel Einhorn provides a summary of novel therapies related to managing and treating diabetes and cardiovascular disease. 


June 19, 2021

Created by

Scripps CME Connection

Related Presenters

Daniel Einhorn, MD, FACP, FACE

Daniel Einhorn, MD, FACP, FACE

Medical Director, Diabetes Program
Scripps Whittier Diabetes Institute
Diabetes and Endocrine Associates
La Jolla, California

Dr. Daniel Einhorn has devoted his practice exclusively to the care of adults with endocrine disorders, including diabetes, thyroid disease, osteoporosis, lipid disorders, polycystic ovarian syndrome, adrenal disease, parathyroid disease ...

View full profile